Results 81 to 90 of about 70,663 (209)

CAR-based cell therapy for autoimmune diseases

open access: yesFrontiers in Immunology
Chimeric antigen receptor (CAR)-based cell therapies, initially designed for oncology, are rapidly advancing as a novel and highly targeted approach for the treatment of autoimmune diseases (AIDs).
Xiu Li   +5 more
doaj   +1 more source

Chimeric antigen receptor modified T-cells for cancer treatment

open access: yesChronic Diseases and Translational Medicine, 2018
T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory ...
Xiao Han, Yao Wang, Wei-Dong Han
doaj   +1 more source

Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy. [PDF]

open access: yes, 2020
Bryostatin 1 is a marine natural product under investigation for HIV/AIDS eradication, the treatment of neurological disorders, and enhanced CAR T/NK cell immunotherapy.
Hardman, Clayton   +8 more
core  

PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models. [PDF]

open access: yes, 2014
Immunology-based interventions have been proposed as a promising curative chance to effectively attack postoperative minimal residual disease and distant metastatic localizations of prostate tumors.
Bobisse, S.   +10 more
core   +3 more sources

Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression

open access: yesNature Communications, 2018
Engineered T cells with chimeric antigen receptor (CAR) are emerging as an effective cancer therapy. Here the authors show that CAR T cells recognizing self-MHC can be ‘tuned’ ex vivo via CAR downregulation and CAR T cell death to generate a CAR T pool ...
Chungyong Han   +13 more
doaj   +1 more source

Synthetic immunology: T-cell engineering and adoptive immunotherapy

open access: yesSynthetic and Systems Biotechnology, 2018
During the past decades, the rapidly-evolving cancer is hard to be thoroughly eliminated even though the radiotherapy and chemotherapy do exhibit efficacy in some degree. However, a breakthrough appeared when the adoptive cancer therapy [1] was developed,
Wen Si, Cheng Li, Ping Wei
doaj   +1 more source

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. [PDF]

open access: yes, 2017
T-cells play a critical role in tumor immunity. Indeed, the presence of tumor-infiltrating lymphocytes is a predictor of favorable patient prognosis for many indications and is a requirement for responsiveness to immune checkpoint blockade therapy ...
Ackerman   +252 more
core   +1 more source

Integrate CRISPR/Cas9 for protein expression of HLA-B*38:68Q via precise gene editing. [PDF]

open access: yes, 2019
The determination of null- or low-expressed HLA alleles is clinically relevant in both hematopoietic stem cell transplantation and solid organ transplantation.
Reed, Elaine F   +2 more
core   +1 more source

Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells. [PDF]

open access: yes, 2020
Head and neck squamous cell carcinomas (HNSCCs) are malignancies that originate in the mucosal lining of the upper aerodigestive tract. Despite advances in therapeutic interventions, survival rates among HNSCC patients have remained static for years ...
Abouyared, Marianne   +10 more
core   +1 more source

Engineering CAR-T cells

open access: yesBiomarker Research, 2017
Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors.
Cheng Zhang   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy